Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GRDN
GRDN logo

GRDN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
34.300
Open
33.170
VWAP
33.45
Vol
605.34K
Mkt Cap
2.12B
Low
32.550
Amount
20.25M
EV/EBITDA(TTM)
26.18
Total Shares
63.32M
EV
2.11B
EV/OCF(TTM)
23.93
P/S(TTM)
1.53
Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.
Show More

Events Timeline

(ET)
2026-03-11
16:30:00
Company Reports Q4 Revenue of $397.6M, Exceeding Expectations
select
2026-03-11
16:30:00
Raises FY26 Adjusted EBITDA Outlook to $120M-$124M
select
2026-01-13 (ET)
2026-01-13
16:40:00
Guardian Reiterates 2025 Revenue Guidance of $1.43B to $1.45B
select
2026-01-13
16:40:00
Guardian Pharmacy Shares Down 2% to $30.65 After FY25 Outlook Affirmed
select
2026-01-13
16:40:00
Guardian Expects 2026 Revenue of $1.4 Billion
select

News

seekingalpha
9.5
03-11seekingalpha
Guardian Pharmacy Services Reports Strong Q4 2025 Earnings
  • Significant Revenue Growth: In Q4 2025, Guardian Pharmacy Services reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth reaching 12%, demonstrating the company's strong performance in acquiring new residents and increasing script volume, thereby solidifying its market position.
  • Adjusted EBITDA Surge: The company achieved a 53% year-over-year increase in adjusted EBITDA to $39.5 million, with margins expanding to 9.9%, reflecting successful operational efficiency and cost control, which enhances the sustainability of future profitability.
  • Strong Cash Flow: As of Q4 2025, the company's cash balance rose to $66 million, up from $36 million in Q3, indicating robust cash generation capabilities that support future investments and acquisitions.
  • Optimistic 2026 Outlook: The company raised its 2026 adjusted EBITDA guidance to $120 million to $124 million, reflecting confidence in ongoing growth drivers, while maintaining revenue expectations between $1.4 billion and $1.42 billion, showcasing adaptability to new pricing policies.
NASDAQ.COM
2.0
03-11NASDAQ.COM
Guardian Pharmacy (GRDN) Earnings Transcript
seekingalpha
9.5
03-11seekingalpha
Guardian Pharmacy Q4 Earnings Exceed Expectations
  • Strong Earnings Report: Guardian Pharmacy Services reported a Q4 GAAP EPS of $0.37, beating expectations by $0.15, which demonstrates robust profitability growth and boosts investor confidence.
  • Revenue Growth: The company achieved Q4 revenue of $397.6 million, exceeding market expectations by $7.56 million, reflecting its competitive position and sustained customer demand in the market.
  • 2026 Outlook: The company raised its adjusted EBITDA guidance for FY 2026 to between $120 million and $124 million, up from the previous range of $115 million to $118 million, indicating management's optimistic outlook for future performance.
  • Stable Revenue Expectations: The revenue forecast for FY 2026 remains between $1.40 billion and $1.42 billion, showcasing the company's confidence in revenue stability, which is expected to continue attracting investor interest.
Newsfilter
9.5
03-11Newsfilter
Guardian Pharmacy Services Reports Strong 2025 Financial Results
  • Significant Revenue Growth: Guardian Pharmacy Services reported fourth-quarter revenue of $397.6 million, a 17% year-over-year increase with organic growth of 12%, indicating strong performance in the long-term care pharmacy market and potential for increased market share.
  • Substantial Net Income Increase: The company achieved a net income of $21.3 million in Q4, up 81% from $11.8 million in the prior year, reflecting successful cost control and operational efficiency, which bolsters investor confidence.
  • Adjusted EBITDA Guidance Raised: Guardian raised its 2026 Adjusted EBITDA outlook to $120 million to $124 million, up from the previous guidance of $115 million to $118 million, signaling management's optimistic expectations for future performance.
  • Vaccine Prescription Volume Growth: The company saw a 9% year-over-year increase in vaccine prescription volumes in 2025, vaccinating over 120,000 residents, demonstrating its commitment to public health services while enhancing brand image and customer loyalty.
Newsfilter
1.0
02-12Newsfilter
Guardian Pharmacy Services to Present at Raymond James Conference
  • Conference Schedule: Guardian Pharmacy Services will present at the Raymond James Institutional Investors Conference on March 2 at 1:40 p.m. Eastern Time, showcasing its expertise in long-term care pharmacy services.
  • Webcast Availability: The session will feature a live audio webcast accessible via the company's website, with a replay available for 90 days post-event, ensuring that investors who cannot attend live can still access the information.
  • Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to enhancing care quality and improving medication adherence through partnerships with long-term care facilities, ultimately reducing care costs.
  • Service Coverage: As of September 30, 2025, Guardian operates over 50 pharmacies nationwide, serving nearly 204,000 residents, demonstrating its significant impact and commitment to the long-term care market.
Businesswire
9.5
02-09Businesswire
Guardian Pharmacy Services to Release Q4 and Full-Year 2025 Financial Results
  • Earnings Release Schedule: Guardian Pharmacy Services will announce its fourth quarter and full-year 2025 financial results after market close on March 11, 2026, providing investors with critical financial performance data to assess the company's operational status.
  • Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results, allowing investors to participate via audio webcast or designated phone numbers, ensuring transparency and timeliness of information.
  • Replay Availability: A replay of the call will be available for approximately 60 days after its conclusion, enabling investors who could not attend in real-time to access important information, thereby enhancing communication between the company and its investors.
  • Company Background: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, serving approximately 204,000 residents.
Wall Street analysts forecast GRDN stock price to rise
2 Analyst Rating
Wall Street analysts forecast GRDN stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
34.00
Averages
34.50
High
35.00
Current: 0.000
sliders
Low
34.00
Averages
34.50
High
35.00
Truist
Buy
maintain
$30 -> $34
AI Analysis
2025-11-14
Reason
Truist
Price Target
$30 -> $34
AI Analysis
2025-11-14
maintain
Buy
Reason
Truist raised the firm's price target on Guardian Pharmacy to $34 from $30 and keeps a Buy rating on the shares. The firm has updated its model to reflect the company's Q3 earnings beat and guidance raise, the analyst tells investors in a research note. Truist is positive on Guardian's leading positioning in the fragmented long-term care pharmacy industry which carries "brisk overarching secular demand drivers".
Oppenheimer
Oppenheimer
Outperform
maintain
$30 -> $35
2025-11-11
Reason
Oppenheimer
Oppenheimer
Price Target
$30 -> $35
2025-11-11
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Guardian Pharmacy to $35 from $30 and keeps an Outperform rating on the shares following quarterly results. Overall, the results were solid, as Guardian continues a methodical approach to growth that unlocks attractive value over time, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GRDN
Unlock Now

Valuation Metrics

The current forward P/E ratio for Guardian Pharmacy Services Inc (GRDN.N) is 28.46, compared to its 5-year average forward P/E of 24.95. For a more detailed relative valuation and DCF analysis to assess Guardian Pharmacy Services Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
24.95
Current PE
28.46
Overvalued PE
27.87
Undervalued PE
22.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
15.17
Current EV/EBITDA
17.25
Overvalued EV/EBITDA
16.77
Undervalued EV/EBITDA
13.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.08
Current PS
1.28
Overvalued PS
1.21
Undervalued PS
0.94

Financials

AI Analysis
Annual
Quarterly

Whales Holding GRDN

A
Aristotle Capital Boston, LLC
Holding
GRDN
+0.84%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Guardian Pharmacy Services Inc (GRDN) stock price today?

The current price of GRDN is 33.51 USD — it has decreased -0.42

What is Guardian Pharmacy Services Inc (GRDN)'s business?

Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.

What is the price predicton of GRDN Stock?

Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is34.50 USD with a low forecast of 34.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Guardian Pharmacy Services Inc (GRDN)'s revenue for the last quarter?

Guardian Pharmacy Services Inc revenue for the last quarter amounts to 397.62M USD, increased 17.44

What is Guardian Pharmacy Services Inc (GRDN)'s earnings per share (EPS) for the last quarter?

Guardian Pharmacy Services Inc. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does Guardian Pharmacy Services Inc (GRDN). have?

Guardian Pharmacy Services Inc (GRDN) has 3400 emplpoyees as of March 12 2026.

What is Guardian Pharmacy Services Inc (GRDN) market cap?

Today GRDN has the market capitalization of 2.12B USD.